Equillium to Present at Jefferies Virtual Healthcare Conference
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 PM ET. This presentation will focus on Equillium's innovative efforts in treating severe autoimmune and inflammatory disorders, particularly through its product candidate itolizumab (EQ001). The live webcast can be accessed on the company’s website and will be available for replay for 30 days.
Details
News Market Reaction – EQ
The recorded move for EQ in the trading session of this news was +0.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., chief medical officer, will present at Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020.
| Date: | Tuesday, June 2, 2020 | |
| Time: | 1:30 PM Eastern Time | 10:30 AM Pacific Time | |
| Location: | Virtual Webcast |
A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Equillium believes that itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing itolizumab into clinical development in the following severe immuno-inflammatory disorders: uncontrolled asthma, acute graft-versus-host disease, and lupus nephritis. For more information, visit www.equilliumbio.com.
Investor Contact
+1-858-412-5302
ir@equilliumbio.com
Media Contact
Cammy Duong
Canale Communications
+1-619-849-5389
cammy@canalecomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.